Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

8.830 +0.310 (+3.64%)
Streaming Delayed Price Updated: 3:34 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Alvotech Announces Changes to the Leadership Team
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure 
From Alvotech
Via GlobeNewswire
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and FMC and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Alvotech Completes $100 Million Convertible Bond Private Placement
From Alvotech
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
From Alvotech
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RH, Alvotech, and TriplePoint and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses to Inquire About Securities Class Action Investigation - ALVO, ALVOW
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Alvotech to Participate in Jefferies Healthcare Conference
From Alvotech
Via GlobeNewswire
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
From Alvotech
Via GlobeNewswire
Alvotech Issues Annual Equality Report Covering 2022
From Alvotech
Via GlobeNewswire
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.